Acute Variceal Bleeding During the SARS-CoV-2 Pandemic: A National Multicenter Observational Study
Authors:
- Gabriel AlloGAGabriel Allo
- Stefanie QuickertSQStefanie Quickert
- Karsten GroßeKGKarsten Große
- Sidar BaysalSBSidar Baysal
- Dirk NierhoffDNDirk Nierhoff
- Christoph Neumann-HaefelinCNChristoph Neumann-Haefelin
- Christoph SchrammCSChristoph Schramm
- Tony BrunsTony Bruns
- Philipp Alexander ReukenPRPhilipp Alexander Reuken
- Martin BürgerMBMartin Bürger
Open Access
- 31 August 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6166
Abstract
Background: The COVID-19 pandemic disrupted healthcare systems globally, raising concerns about its negative impact on patients with chronic liver diseases by contributing to hepatic decompensations such as acute variceal bleeding (AVB). This study aimed to evaluate the impact of the COVID-19 pandemic on clinical outcomes in cirrhotic patients with AVB in Germany. Methods: This retrospective national multicenter study compared patients with cirrhosis and AVB treated at four tertiary care centers in Germany before (2016–2020) and during the pandemic (2020–2022). The primary endpoint was 6-week mortality, and secondary outcomes included infections, transfusion requirement and rebleeding. Results: The baseline characteristics of the 247 patients were largely comparable between the two groups, however metabolic dysfunction-associated steatotic liver disease was more prevalent during the pandemic compared to the pre-pandemic period (12.5% vs. 4.8%, p = 0.048). Only one patient tested positive for SARS-CoV-2. Six-week mortality (32.2% vs. 30.1%; p = 0.767) and rebleeding rates (22.8% vs. 22.3%; p = 1.000) did not differ significantly between groups. Interestingly, intubation rates, length of stay on the intensive care unit, post AVB infection rates and types of infection were also comparable (all p > 0.05), while transjugular intrahepatic portosystemic shunt placement (TIPS) after bleeding was performed more frequently during the pandemic (23.2% vs. 11.3%, p = 0.019). Conclusions: Relevant patient-related AVB outcomes were unaffected during the COVID-19 pandemic. These findings suggest the resilience of critical AVB management practices in German tertiary centers. The increased use of TIPS and MASLD prevalence during the pandemic may reflect evolving clinical practice and patient profiles warranting further investigation.Keywords
This publication has 35 references indexed in Scilit:
- COVID‐19 mortality in cirrhosis is determined by cirrhosis‐associated comorbidities and extrahepatic organ failure: Results from the multinational LEOSS registryUnited European Gastroenterology Journal, 2022
- Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphomaInfection, 2022
- COVID-19 pandemic-related mortality, infection, symptoms, complications, comorbidities, and other aspects of physical health among healthcare workers globally: An umbrella reviewInternational Journal of Nursing Studies, 2022
- Mortality Trends in Chronic Liver Disease and Cirrhosis in the United States, Before and During COVID-19 PandemicClinical Gastroenterology and Hepatology, 2021
- Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxisJournal of Hepatology, 2021
- High rates of 30-day mortality in patients with cirrhosis and COVID-19Journal of Hepatology, 2020
- EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosisJournal of Hepatology, 2018
- CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care settingAmerican Journal of Infection Control, 2008
- Definitions, methodology and therapeutic strategies in portal hypertensionJournal of Hepatology, 1992
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987